Merck, Inc.
🇺🇸United States
A Study of a Novel Investigational Drug in Rheumatoid Arthritis Patients (MK-0873-012)(COMPLETED)
- First Posted Date
- 2005-08-22
- Last Posted Date
- 2015-07-30
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 106
- Registration Number
- NCT00132769
An Investigational Drug Study In Patients With COPD (Chronic Obstructive Pulmonary Disease) (MK-0873-005)
Phase 2
Terminated
- Conditions
- Lung DiseasesPulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2005-08-22
- Last Posted Date
- 2018-10-12
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 604
- Registration Number
- NCT00132730
Safety of SCH 530348 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention (Study P03573)
Phase 2
Completed
- Conditions
- Arterial Obstructive DiseasesCoronary Disease
- First Posted Date
- 2005-08-22
- Last Posted Date
- 2017-05-25
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1030
- Registration Number
- NCT00132912
A Two Year Safety and Efficacy Study in Obese Patients (0364-015)(TERMINATED)
- First Posted Date
- 2005-08-18
- Last Posted Date
- 2015-02-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 2400
- Registration Number
- NCT00131404
An Eighteen Month Efficacy and Safety Study in Obese Patients (0364-020)(COMPLETED)
Phase 2
Completed
- Conditions
- Obesity and Obesity-related Medical Conditions
- First Posted Date
- 2005-08-18
- Last Posted Date
- 2016-06-07
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 500
- Registration Number
- NCT00131430
A Study of MK0364 in Obese Patients (0364-014)
Phase 3
Terminated
- Conditions
- Obesity
- First Posted Date
- 2005-08-18
- Last Posted Date
- 2015-04-03
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 2400
- Registration Number
- NCT00131391
Concomitant Use and Staggered Use of Vaccine and Oral Poliovirus (OPV) in Healthy Infants (V260-014)(COMPLETED)
Phase 3
Completed
- Conditions
- Rotavirus InfectionsGastroenteritis
- Interventions
- Biological: Rotavirus Vaccine, Live, Oral, Pentavalent
- First Posted Date
- 2005-08-16
- Last Posted Date
- 2015-04-01
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 735
- Registration Number
- NCT00130832
A Study to Evaluate Safety, Tolerability, and Immunogenicity of an Investigational Zoster Vaccine In Subjects With a History of Varicella (Chickenpox)(V211-010)(COMPLETED)
Phase 3
Completed
- Conditions
- Herpes Zoster
- First Posted Date
- 2005-08-16
- Last Posted Date
- 2015-01-26
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 368
- Registration Number
- NCT00130793
An Investigational Drug Co-Administered With Insulin in Patients With Type 2 Diabetes (0478-065)
Phase 3
Terminated
- Conditions
- Type 2 Diabetes Mellitus
- First Posted Date
- 2005-08-16
- Last Posted Date
- 2016-09-07
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 600
- Registration Number
- NCT00130806
A Study in Pediatric Patients With Cystic Fibrosis Lung Disease
Phase 2
Completed
- Conditions
- Cystic Fibrosis
- First Posted Date
- 2005-08-15
- Last Posted Date
- 2013-05-22
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 13
- Registration Number
- NCT00130182
- Locations
- 🇺🇸
General Clinic Research Center University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸The Minnesota CF Center, Minneapolis, Minnesota, United States
🇺🇸The Children's Hospital, Denver, Colorado, United States
© Copyright 2025. All Rights Reserved by MedPath